ホーム>>Signaling Pathways>> Immunology/Inflammation>> Innate Immunity>>SN-011

SN-011 (Synonyms: GUN35901)

カタログ番号GC49400

SN-011 は強力かつ選択的なマウスおよびヒトの STING 阻害剤であり、STING シグナル伝達に対する IC50 は 76 nM です。

Products are for research use only. Not for human use. We do not sell to patients.

SN-011 化学構造

Cas No.: 2249435-90-1

サイズ 価格 在庫数 個数
1 mg
$27.00
在庫あり
5 mg
$99.00
在庫あり
10 mg
$153.00
在庫あり
25 mg
$261.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

SN-011 is a stimulator of interferon genes (STING) antagonist.1 It binds to the STING cyclic dinucleotide binding site (Kd = 4.03 nM) and inhibits 2’3’-cGAMP-induced Ifnb expression in mouse embryonic fibroblasts (MEFs), mouse bone marrow-derived macrophages (BMDMs), and human foreskin fibroblasts (HFFs; IC50s = 127.5, 107.1, and 502.8 nM, respectively). SN-011 (1 µM) impairs recruitment of IFN regulatory factor 3 (IRF3) or TANK-binding kinase 1 (TBK1) to the STING signalosome in HEK293T cells overexpressing tagged wild-type or SAVI-linked mutant STING and IRF3 or TBK1, as well as inhibits translocation of STING from the endoplasmic reticulum (ER) to the Golgi induced by herpes simplex virus 1 (HSV-1) in HFFs. In vivo, SN-011 (5 mg/kg) increases survival and reduces Ifnb mRNA levels in the Trex1-/- mouse model of Aicardi-GoutiÈres syndrome, an autoimmune disorder characterized by constitutive activation of cGAS and IFN overproduction.

1.Hong, Z., Mei, J., Li, C., et al.STING inhibitors target the cyclic dinucleotide binding pocketProc. Natl. Acad. Sci. USA.118(24)e2105465118(2021)

レビュー

Review for SN-011

Average Rating: 5 ★★★★★ (Based on Reviews and 10 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SN-011

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.